-
Product Insights
Marginal Zone B-cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Marginal Zone B-cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Marginal Zone B-cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Marginal Zone B-cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nivolumab in Neuroblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Neuroblastoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nivolumab in Neuroblastoma Drug Details: Nivolumab (Opdivo, Opdyta) is a human IgG4...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Disufenton Sodium in High-Grade Glioma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Disufenton Sodium in High-Grade Glioma Drug Details: Disufenton sodium (NXY-059, OKN-007) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMC-002 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMC-002 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMC-002 in Diffuse Large B-Cell Lymphoma Drug Details: IMC-002...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMC-002 in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMC-002 in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMC-002 in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: IMC-002...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMC-002 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMC-002 in Mantle Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMC-002 in Mantle Cell Lymphoma Drug Details: IMC-002 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – IMC-002 in Gallbladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMC-002 in Gallbladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMC-002 in Gallbladder Cancer Drug Details: IMC-002 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMC-002 in Metastatic Biliary Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMC-002 in Metastatic Biliary Tract Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMC-002 in Metastatic Biliary Tract Cancer Drug Details: IMC-002...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMC-002 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMC-002 in Follicular Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMC-002 in Follicular Lymphoma Drug Details: IMC-002 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMC-002 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMC-002 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMC-002 in Marginal Zone B-cell Lymphoma Drug Details: IMC-002...